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CircRNA-protein complexes: 
IMP3 protein component defines 
subfamily of circRNPs
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Oliver Rossbach1, Stefan Reich2, Jan Medenbach2 & Albrecht Bindereif 1
Circular RNAs (circRNAs) constitute a new class of noncoding RNAs in higher eukaryotes generated 
from pre-mRNAs by alternative splicing. Here we investigated in mammalian cells the association 
of circRNAs with proteins. Using glycerol gradient centrifugation, we characterized in cell lysates 
circRNA-protein complexes (circRNPs) of distinct sizes. By polysome-gradient fractionation we found 
no evidence for efficient translation of a set of abundant circRNAs in HeLa cells. To identify circRNPs 
with a specific protein component, we focused on IMP3 (IGF2BP3, insulin-like growth factor 2 binding 
protein 3), a known tumor marker and RNA-binding protein. Combining RNA-seq analysis of IMP3-co-
immunoprecipitated RNA and filtering for circular-junction reads identified a set of IMP3-associated 
circRNAs, which were validated and characterized. In sum, our data suggest that specific circRNP 
families exist defined by a common protein component. In addition, this provides a general approach to 
identify circRNPs with a given protein component.
Circular RNAs (circRNAs) are a new and large class of noncoding RNAs comprised of hundreds to thousands 
of members, and present in all eukaryotes investigated so far, from protozoa, yeast to human1–2. Although single 
examples of circular RNAs had been known for decades, starting with the plant-pathogenic viroid RNAs3, only 
in 2012/13 circRNAs were rediscovered as a new class of noncoding RNAs4–6. This was based on RNA-seq and 
corresponding bioinformatic analyses, relying on the circRNA-characteristic splice junction (“back-splice”).
This type of circRNAs contains one or more adjacent exons, that are spliced out of the pre-mRNA to yield 
instead of the normal, linear protein-coding mRNA a circular RNA product. CircRNAs are cell-type specifically 
expressed, more stable than the corresponding linear mRNA, evolutionarily conserved, and mostly cytoplasmic in 
cellular localization1. Often circularizing exons are flanked by long introns, which contain reverse-complementary 
repeats, in human frequently Alu repeats; this presumably allows a cross-exon base-pairing interaction, making 
circularization more favorable5,7–10. We have recently demonstrated by mutational analysis that circularization 
requires the canonical splice signals, including branch point and pyrimidine tract, arguing for the normal spli-
ceosomal machinery and a mode of alterntative splicing to function here9. Exon circularization competes with 
normal linear splicing, and it is largely unknown what governs the ratio circular-versus-linear product, except 
for the case of the MBNL circRNA, where the protein product autoregulates its own circular/linear processing 
pathways11. In addition, the splicing regulator protein QKI can control circRNA formation, by binding to intronic 
QKI sites flanking the circularizing exon12. Note that besides these exonic-type circRNAs, there is also a class of 
intron-derived circular RNA species13.
Functionally, circRNAs are still largely uncharacterized, except for a miRNA sponge function, which has been 
experimentally validated for two cases, ciRS-7 and SRY circRNAs6,14, and an autoregulatory potential demon-
strated for MBNL expression in Drosophila11. Several other, hypothetical roles have been discussed, for example 
in protein sponging, allostery, complex assembly, or antisense activity1,15. Translation of circRNAs to peptides or 
proteins represents another potential biological function, and earlier studies had demonstrated that translation 
from circular RNA constructs is in principle possible, for example by inserting viral internal ribosome entry sites 
(IRES) or under in vitro conditions16,17. However, no natural examples of circRNA translation have been reported 
so far.
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Here we describe the initial characterization of circRNA-protein complexes (circRNPs). For a set of relatively 
abundant circRNAs we demonstrate that they exist in the form of discrete RNPs, stable in sedimentation analysis 
through glycerol gradient centrifugation. We then focus on IMP3 (= IGF2BP3, insulin-like growth factor 2 bind-
ing protein 3), a known oncofetal and tumor marker RNA-binding protein with multiple post-transcriptional 
roles18–20. In particular, there is evidence for IMP3 playing a role in pancreas development, with IMP3 being 
overexpressed in pancreatic ductal adenocarcinomas18,21. Here we combined immunoprecipitation, RNA-seq, 
and bioinformatic circular-junction analysis, to identify a subfamily of circRNAs stably associated with IMP3, fol-
lowed by validation and further characterization of several examples of IMP3-containing circRNPs. This provides 
a general approach to identify circRNPs carrying a specific protein component. Our data indicate that specific 
proteins define subclasses of circRNPs possibly linked by a common function or biogenesis pathway.
Results and Discussion
Evidence for distinct cytoplasmic circRNPs in mammalian cells. To identify circRNA-protein com-
plexes, we subjected cytoplasmic extract (S100) from HeLa cells to glycerol gradient fractionation, whereby RNAs 
and RNPs sediment according to their molecular size and shape. We focussed the analysis on S100 extract, since 
circRNAs predominantly localize in the cytoplasm. 22 fractions were collected, followed by RNA preparation 
from every second fraction and RT-PCR assays for 12 relatively abundant circRNAs, based on circular-junc-
tion-specific primers. In parallel, and for direct comparison, total RNA prepared from S100 extract was frac-
tionated through glycerol gradients under the same conditions, followed by the RT-PCR analysis of the circRNA 
distribution across the gradient (Fig. 1A; for quantitation of these results, see Fig. 1B).
The free circRNAs distribute in the glycerol gradient between fractions #7 and #11, depending on the size of 
the respective circRNA (219 nts for GSE1 to 1,099 nts for HIPK3). In contrast, in the S100 extract the circRNAs 
peak at fractions #9 to #14, but in most cases with a clear peak, indicating that each circRNA exists in the form of 
a major distinct large complex in the 10–15 S region. To obtain direct evidence that this is due to protein compo-
nents, we also analyzed the gradient distribution of circRNAs after proteinase K treatment: Clearly, the circRNAs 
shifted back to the position of free RNA (Fig. 1B and Supplementary Fig. S1), demonstrating that the large com-
plexes we detect in S100 extract represent circRNPs. The difference between the positions of free circRNAs and 
respective circRNPs are between two fractions (for the small circRNAs, such as GSE1 or LPAR1) and four frac-
tions (for the larger circRNAs, such as GLIS3 or CDYL2); this shift corresponds to a molecular mass difference of 
approximately 50 to 110 kDa (two to four fractions).
We have also used the same approach to identify circRNP complexes in a cytoplasmic extract prepared under 
less stringent conditions than S100 (without the centrifugation step at 100,000 × g), as well as in nuclear extract 
(Supplementary Fig. S1): CircRNPs detected in cytoplasmic extract were generally larger than the corresponding 
complexes from S100 extract (differing by two to four fractions), and they were more heterogeneous in gra-
dient sedimentation, but also protein-dependent; circRNPs in nuclear extract, as far as they were detectable 
(see CAMSAP1, GLIS3, and HIPK3), behaved similarly as in cytoplasmic extract.
In sum, our analysis provided biochemical evidence for that each of the circRNAs tested exists in cells as cir-
cRNPs of distinct sizes.
Selected abundant circRNAs are not associated with polysomes. To analyze whether endoge-
nous circRNAs are associated with polysomes and may be translated in HeLa cells, we selected 10 out of the 12 
abundant circRNAs described above. Cells were first treated with cycloheximide to stabilize the RNA-ribosome 
interaction, or, as an important control, with puromycin, which releases ribosomes from mRNA being translated 
(Fig. 2A). Cytoplasmic extracts were prepared, loaded onto 10–50% sucrose gradients, and subjected to ultra-
centrifugation. Following fractionation, the distribution of linear HIPK3 mRNA (as a positive control) and of 10 
abundant circRNAs across the gradient was determined by RT-PCR (Fig. 2B). As expected, we detected for the 
linear HIPK3 mRNA a characteristic shift upon puromycin treatment, indicative of translational activity (Fig. 2B, 
HIPK3 linear mRNA, from fractions #10–11 to 6–7). In contrast, the 10 circular RNAs analyzed showed a similar 
sedimentation across the gradient, with peaks in fractions #1–3 (that is up to the 40S region), and with only very 
minor quantities (if detectable at all) in the monosome-to-polysome fractions (#4–11). Importantly, we did not 
observe any significant shift of these cirRNAs upon puromycin treatment (compare gradient distributions CHX 
versus Puro). Only for HIPK3 we found considerable quantities of circRNPs in the polysome region, yet with-
out any major change upon puromycin treatment. Note that for CAMSAP1 circRNA we observed two RT-PCR 
products of very similar sizes (see fractions #6–11): The bottom band represents the circular RNA; the top band 
(marked with an asterisk) is due to mispriming at the linear CAMSAP1 mRNA and shifts upon puromycin treat-
ment, as expected from translationally active linear mRNA.
We conclude that our polysome gradient analysis did not yield any evidence for circRNAs to be efficiently 
translated, as shown here for 10 abundant circRNAs in HeLa cells. This is consistent with three other recent 
reports, based on ribosome-footprinting and polysome-gradient data from mammalian cell lines5,22 and mouse 
brain23. Although our carefully controlled initial analysis argues against a widespread translational potential of 
circRNAs, obviously this does not exclude that there may be natural cases of circRNA translation, for example 
restricted to a small subset of specialized circRNAs, or to certain cell types, tissues, developmental stages, or 
growth conditions.
Identification of IMP3-associated circRNAs. To characterize circRNPs further, we initially tried to 
use the iCLIP approach (individual-nucleotide crosslinking-immunoprecipitation), which allows mapping of 
RNA-protein contacts at single-nucleotide resolution24. Because of the initial immunoprecipitation (IP) step, 
this approach had to focus on a specific protein to be characterized as a potential circRNP component. We 
chose IMP3 (also called IGF2BP3, insulin-like growth-factor 2 binding protein 3), a known multifunctional 
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RNA-binding protein implicated in posttranscriptional gene regulation and an established tumor marker pro-
tein (see Introduction). We mapped transcriptome-wide binding sites for IMP3 protein by iCLIP in HepG2 cells 
(human liver carcinoma cell line), followed by searching for iCLIP tags spanning the characteristic circular junc-
tions (see Supplementary Fig. S2 for the initial IMP3 iCLIP analysis and specific examples of IMP3 targets). 
However, it turned out that due to short sequencing reads and limited sequencing depth, our analysis of these 
IMP3-iCLIP data was not suitable for circRNA identification.
Therefore we developed an alternative approach, combining IP, RNA-seq, and bioinformatic filtering for cir-
cRNA junction sequences (Fig. 3A).
First, cell lysates were prepared from cultured HepG2 cells, in parallel also from PANC1 and PATU cells, two 
human pancreas tumor-derived cell lines. All of these three cell lines express IMP3 protein (data not shown).
Second, IMP3-associated RNAs were obtained by anti-IMP3 immunoprecipitation, RNA-seq library con-
struction, and sequencing (~127.5 mio. 2 × 100 bp paired-end reads, Illumina HiSeq 2000). The major part of 
the total sequenced reads (~127.5 mio.) was from the IMP3-immunoprecipitated material (~36.9/42.0/48.2 mio. 
Figure 1. Evidence for distinct circRNA-protein complexes in mammalian cells. (A) Sedimentation 
profiles of circRNPs/circRNAs. Cytoplasmic S100 extract and corresponding free RNA from HeLa cells were 
fractionated by glycerol gradient centrifugation (#1–22 from top to bottom; the last fraction containing the 
resuspended pellet), followed by RT-PCR analysis of 12 abundant circRNAs across the gradient (ordered from 
top to bottom according to their sizes; given in nucleotides). The positions of ribosomal RNA size markers are 
indicated (5S, 18S, and 28S), as well as the shift of the circRNA vs. circRNP peak fractions (brackets).  
(B) Quantitation of circRNA distribution across gradient, comparing free RNA prepared from extract (RNA, 
in blue), cytoplasmic S100 fraction (extract, in red), and proteinase K-treated extract (extract + PK, in dashed 
lines). Data from panel A (RNA/extract) and from Supplementary Fig. S1A (extract + PK) were used for 
quantitation.
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reads for the respective HepG2/PANC1/PATU libraries; Fig. 3B); total read numbers from the control immuno-
precipitations were below 0.5%.
Third, IMP3-associated circRNAs were predicted by extracting circRNA-specific junction reads, resulting 
in 3,257/2,929/10,377 reads for the respective HepG2/PANC1/PATU libraries (Fig. 3B). From the ~5,000 puta-
tive circRNAs, a set of 34 circRNAs containing exons from 25 protein-coding genes were considered with high 
confidence to be IMP3-associated (≥ 30 circRNA-specific junction reads in at least one of the 3 cell lines; see 
Supplementary Table S1). For further experimental analysis, 8 different circRNAs with high circRNA-specific 
junction read counts in all three cell lines were selected (Fig. 3C, D).
As evidence for the circularity of these putative IMP3 target circRNAs, we assayed their resistance towards 
RNase R, an exo-ribonuclease, using RT-PCR specific for the circular versus a downstream linear splice junction: 
All circRNA candidates selected showed high RNase R resistance, relative to the corresponding linear isoform 
from the same gene (Fig. 3D).
An IMP3-associated family of circRNPs: validation, characterization, and specific IMP3-circRNA 
binding. To validate and quantitatively characterize the IMP3 association of a subgroup of circRNAs we did 
Figure 2. Major circRNAs in HeLa cells are not associated with polysomes. (A) Polysome gradient profiles 
of HeLa cytoplasmic extracts after treatment with cycloheximide or puromycin. The RNA distribution (A260nm) 
and the positions of ribosomal size markers are indicated (40S/60S ribosomal subunits, 80S initiation complex/
monosomes, and polysome region). (B) Analysis of circRNA fractionation on polysome gradients, comparing 
profiles after cycloheximide (CHX) or puromycin (Puro) treatment. After RNA extraction, fractions were 
pooled (#1, #2–3, #4–5, #6–7, #8–9, and #10–11), followed by RT-PCR analysis of ten abundant circRNAs across 
the gradient. HIPK3 linear mRNA was used as a positive control for puromycin-induced mRNA release from 
polysomes (top two panels); the ten circRNAs (from GSE1, 219 nt, to HIPK3, 1099 nt) are ordered according 
to their sizes. Mispriming products corresponding to the linear mRNA of CAMSAP1 in polysome fractions 
(CAMSAP1 circ, #6–11) are marked by asterisks.
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anti-IMP3 immunoprecipitations from lysates of HepG2, PANC1, and PATU cells, followed by RNA purification 
and semiquantitative RT-PCR assays of circular and linear isoforms for three IMP3 circRNP candidates (CDYL, 
NFATC3, and ANKRD17), comparing in each case input (5%) and immunoprecipitate (90%); as a negative IP 
control, anti-FLAG IPs were analyzed in parallel (Fig. 4A). As another negative control, both linear and circu-
lar variants of CAMSAP1 were analyzed; the linear FTL mRNA, which we knew from our iCLIP study to be 
IMP3-associated (see above and Supplementary Fig. S2B), served as a positive control.
As a result, we were able to confirm all three IMP3 circRNP candidates as IMP3 targets (CDYL, NFATC3, and 
ANKRD17); both linear and circular isoforms of CAMSAP1, in contrast, exhibited only background or undetect-
able levels after IMP3 immunoprecipitation. These semiquantitative results were further confirmed by real-time 
PCR assays (Fig. 4B): The anti-IMP3 IP efficiencies were 4–5% for CDYL, 11–18% for NFATC3, and 16–24% for 
ANKRD17 circRNA, with only minor differences between the three cell lines.
As the next step, we fractionated HeLa cytoplasmic extract (S100) by glycerol gradient centrifugation, in 
parallel with total RNA prepared from the same extract, and proteinase K-treated S100 extract (Fig. 4C). The two 
major IMP3-associated circRNAs, NFATC3, and ANKRD17, were detected in the gradient fractions by RT-PCR, 
using circular-junction-specific primers, analogously to the characterization of abundant circRNAs (see above 
and Fig. 1). Both IMP3-associated circRNAs showed a distinct peak, suggesting that a predominant complex 
exists, which concentrated in fractions #15 (NFATC3) and #17 (ANKRD17). Corresponding free circRNAs sed-
imented approximately four fractions more towards the top, and very similarly as deproteinized circRNPs, con-
firming that the circRNA complexes contain protein components. We noted that the free circRNAs for NFATC3 
Figure 3. Identification of IMP3-associated circRNAs: anti-IMP3 co-immunoprecipitation and RNA-seq. 
(A) Strategy of identification of IMP3-associated circRNAs. For details, see Results. (B) Summary of RNA-seq 
analysis, based on immunoprecipitates from three different cell lines (HepG2, PANC1, and PATU), for each 
case comparing mock control (m) and after IMP3 immunoprecipitation (IP). Total and uniquely mapped read 
counts (each in mio reads), as well as circRNA specific junction reads are listed. (C) Candidate list of 12 IMP3-
associated circRNAs, including number of circularized exons and their total length (in nts). For three circRNAs, 
different circRNA isoforms (as indicated) were identified to be IMP3-associated. (D) Evidence for circularity 
of IMP3-associated circRNAs. Total RNA from HepG2 cells was mock- or RNase R-treated (− /+ ), followed 
by RT-PCR detection of circular and linear isoforms of IMP3 targets. The linear mRNA of FTL served as a 
positive control for RNase R digestion. M, markers (100, 200, and 300 bp). Results are shown after agarose gel 
electrophoresis (bottom) and by quantitation (top; − /+ RNase R ratio), normalized to the mock-treated sample. 
In lanes with multiple PCR products the band specific for the respective circRNA is marked by an asterisk.
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Figure 4. IMP3 protein specifically and stably bound to circRNA family: validation and characterization. 
(A) Validation of IMP3 bound to specific circRNAs. Lysates of HepG2, PANC1, and PATU cells were subjected 
to immunoprecipitation with anti-IMP3 antibodies (IP), or as mock control, with anti-FLAG antibodies (m). 
Co-precipitated RNA was purified and assayed by RT-PCR for FTL mRNA (positive control), CAMSAP1 
(negative control circRNA), and for the putative IMP3-associated circRNAs CDYL, NFATC3, and ANKRD17. 
For each of the circRNAs, the linear isoform of the respective gene was tested in addition (circ/lin; 90% of 
the mock- and IMP3-immunoprecipitates were used in RT-PCR). In addition, 5% of the input material was 
assayed (I). M, markers (in bp). (B) Quantitative immunoprecipitation analysis of IMP3-circRNA association 
in three cell lines (HepG2, PANC1, and PATU). For the same set of IMP3 circRNA targets and controls as 
shown in panel A, the immunoprecipitation efficiences were determined by RT-qPCR assays (% of input; 
statistical deviations based on biological duplicates). (C) Sedimentation profiles of IMP3-containing circRNPs. 
Cytoplasmic S100 extract from HeLa cells (extract), corresponding free RNA (RNA), and proteinase K-treated 
extract (extract + PK) were fractionated by glycerol gradient centrifugation (#1–22; the last fraction contains 
the resuspended pellet), followed by RT-PCR analysis of two IMP3-containing circRNAs (NFATC3 and 
ANKRD17). The relatively low recovery of circRNAs NFATC3 (1298 nt) and especially ANKRD17 (1832 nt), 
the largest circRNAs analyzed in S100 extract, may be caused by the higher tendency of such large circRNPs 
to aggregate and form precipitates, which were lost in the pellet fraction. The positions of ribosomal RNA 
size markers are indicated (5S, 18S, and 28S), as well as the shift of the circRNA vs. circRNP peak fractions 
(brackets). For comparison, the distribution of total IMP3 protein across the gradient was visualized by Western 
blotting in extract and, as a control, in proteinase K-treated extract. (D) IMP3 immunoprecipitation efficiencies 
of gradient-purified NFATC3 and ANKRD17 circRNPs. HeLa cytoplasmic S100 extract was gradient-
fractionated, and NFATC3 and ANKRD17 circRNPs were IMP3-immunoprecipitated from the respective 
peak fractions (NFATC3, #15; ANKRD17, #17), using CAMSAP1 circRNA (peak fraction #11) and anti-eIF4E 
immunoprecipitation as negative controls. Immunoprecipitation efficiencies (% of input; statistical deviations 
based on technical triplicates) were determined by RT-qPCR.
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(1298 nt) and ANKRD17 (1832 nt) show a broader distribution across the gradient (Fig. 4C), similarly as the free 
circRNAs of CDYL2 (592 nt) and HIPK3 (1099 nt; Fig. 1), compared with smaller circRNAs. This may reflect the 
higher potential of large circRNAs to form alternative structures (or aggregates by RNA-RNA interactions) that 
would affect their sedimentation behavior. The distribution of IMP3 protein was detected by Western blotting in 
the same gradient fractions: A large portion of IMP3 protein peaked in fraction #5, most likely representing free 
protein, but the rest of it distributed across fractions #7–19, that includes the region where the IMP3 circRNPs 
fractionated.
Finally, we measured IMP3 association for two of these gradient-purified circRNPs, NFATC3 and ANKRD17, 
using anti-IMP3 immunoprecipitation from the respective peak fractions (NFATC3, #15; ANKRD17, #17), fol-
lowed by real-time RT-PCR for the circular splice junctions; as negative controls we used IP against eIF4E, an 
abundant cytoplasmic RNA-binding protein, which binds to the cap structure of linear mRNAs, and CAMSAP1 
circRNA, which was not among the IMP3 targets identified (Fig. 4D). The IP efficiencies of the NFATC3 
and ANKRD17 IMP3 circRNPs with IMP3 antibodies were 6.4 and 21.7%, respectively, background bind-
ing below 1.3% (anti-eIF4E IP) or undetectable (for CAMSAP1 circRNP). In sum, we thereby confirmed that 
IMP3-containing circRNPs of the NFATC3 and ANKRD17 circRNAs exist and are stable through glycerol gra-
dient centrifugation.
Specificity of IMP3-circRNA binding based on a SELEX-derived C/A-rich motif. To explain the 
specific and stable IMP3 association with a subset of circRNAs, we further investigated the intrinsic RNA-binding 
specificity of the IMP3 protein. We therefore applied an in vitro SELEX procedure, using four rounds of selection 
with an N20 RNA pool and recombinant GST-IMP3, which contains the full-length IMP3 protein (Fig. 5A). GST 
protein served as a control in parallel selection and enrichment rounds. After each round, aliquots of the RT-PCR 
amplified RNA pools were analyzed by Solexa sequencing, resulting in between 0.56 and 0.70 mio sequence tags 
per cycle for GST-IMP3 (for the GST control: 1.68 mio tags after the fourth cycle).
The representation of each of the 256 possible tetramer motifs was determined after each SELEX cycle and the 
enrichment of each tetramer evaluated by z-score values. Figure 5B shows as a heatmap only the top 20 tetramers 
(ordered according to their z-score sum of the four SELEX rounds with GST-IMP3 protein) and the bottom 10 
tetramers, in particular how these motifs changed over the four cycles (R1 to R4). Clearly, the top 10 tetramers 
(highlighted in yellow) are highly C/A-rich, with CACA, ACAC, and AACA becoming enriched most strongly, 
consistent with the “compendium motif ” of Ray et al.26. On the other extreme, the bottom 10 motifs are all G/C- 
or G/T-rich. A corresponding analysis of hexamer motif enrichment confirmed these results (Fig. 5B).
To analyze whether these SELEX-based IMP3 RNA-binding motifs are enriched in the IMP3-associated cir-
cRNAs, we calculated the sum of the top 10 tetramer motif counts in 34 IMP3-bound circRNAs, normalized to 
100 nts sequence length (Fig. 5C, left part). These motif counts in this IMP3 target circRNA group were compared 
with those in a non-target group (circRNAs well-expressed in HepG2 cells, n = 117; for details, see Methods). 
Based on kernel density estimation and a p-value of 1.077e-07 (Welch two sample t-test), we conclude that 
C/A-rich motifs are significantly enriched in IMP3-associated circRNAs (Fig. 5C, right part).
In conclusion, the IMP3 protein by itself can recognize certain C/A-rich motifs. The specificity of IMP3 RNA 
recognition is most likely complex, due to its domain structure with two RNA-recognition (RRMs) and four KH 
motifs. This may contribute to why the motif from a PAR-CLIP-based in vivo study in HEK293 cells (CAUU)25 
differed from an in vitro analysis (CA-rich motif)26. There may also be additional factors, for example associated 
other RNA-binding proteins, that modulate the RNA-binding preference of IMP3 in vivo or act in a combinato-
rial manner. Therefore we have to consider that IMP3 may bind in 3′ -UTR versus coding-exon regions through 
different ways and with different cofactors, reflected in different enriched motifs.
Methods
Glycerol gradient sedimentation analysis. Cytoplasmic S100 fraction (S100), cytoplasmic extract 
(CE; prepared without the centrifugation step at 100,000 × g), and nuclear extract (NE) from HeLa cells 
(IpraCell), as well as RNA isolated from S100 extract (RNA), proteinase K-treated S100 (S100 + PK), and protein-
ase K-treated cytoplasmic extract (CE + PK) were analyzed by glycerol gradient centrifugation. For the gradient 
with free RNA, RNA from 500 μ l S100 was isolated by TRIzol (Ambion). Proteinase K (PK) treatment was done 
by incubating 500 μ l extract (S100/CE) in 1x PK buffer with 100 μ g/ml PK (Roth) and 0.5% SDS for one hour at 
37 °C. Samples of 500 μ l each were loaded onto 10–30% (v/v) glycerol gradients (10 ml) and subjected to ultracen-
trifugation for 16 hours at 4 °C (32,000 rpm; SW-40). After centrifugation, the gradient was fractionated manually 
into 21 fractions of 500 μ l each, whereas the resuspended pellet was labeled as fraction 22. RNA was isolated from 
200 μ l of every second fraction by TRIzol (Ambion), followed by RT-PCR (described below). PCR products were 
analyzed on 2% agarose gels and quantified (GeneTools software; Syngene). As size markers, the sedimentation of 
ribosomal RNAs was analyzed (Agilent 2100 Bioanalyzer; RNA 6000 Nano Kit, Agilent).
Polysome fractionation. HeLa cells were treated with cycloheximide (100 μ g/ml) for 10 min or puromy-
cin (250 μ g/ml) for 30 min, washed once with ice-cold PBS and lysed for 10 min on ice in gradient-lysis buffer 
(5 mM Tris-HCl pH 7.4, 1.5 mM KCl, 5 mM MgCl2, 0.5% Triton X-100, 0.5% deoxycholate, Invitrogen RNaseOut, 
Fermentas ProteoBlock), containing cycloheximide or puromycin. After centrifugation (10 min at 20,000 × g), 
the cytoplasmic lysates were loaded onto 10–50% (w/v, 12 ml) linear sucrose gradients (20 mM Tris-HCl pH 
7.4, 150 mM NaCl, 5 mM MgCl2, 1 mM DTT, and 100 μ g/ml cycloheximide, prepared with the BioComp gra-
dient master). Gradients were centrifuged for 3 h at 35,000 rpm in a Beckman centrifuge (SW40Ti rotor), fol-
lowed by fractionation (12 × 1ml), using the Brandel tube piercer (ISCO) in combination with an ÄKTA purifier 
(GE Healthcare). RNA was isolated from 500 μ l of the fractions (#1–11) by phenol/chloroform extraction (Roth), 
followed by RT-PCR (described below).
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IMP3 iCLIP. The iCLIP experiment was performed with HepG2 cells. For immunoprecipitation, IMP3-specific 
polyclonal antibodies (Millipore) were used, for the negative control the antibody was omitted. For validation of 
immunoprecipitation by Western blotting, an IMP3-specific monoclonal antibody (E2, Santa Cruz) was used. 
Figure 5. IMP3 binding motif derived from SELEX-seq analysis: enrichment in IMP3-associated circRNAs. 
(A) Schematic representation of SELEX-seq procedure and data analysis. Using GST-IMP3 (GST as control) and 
an N20 RNA pool, IMP3 RNA-binding sequences were enriched through four SELEX rounds. After each round 
(R1–R4) and for the GST control, aliquots were taken for Solexa sequencing (number of reads given in mio), 
followed by motif enrichment analysis (see panel B). (B) Tetramer and hexamer enrichment for the four SELEX 
rounds with GST-IMP3 (R1–R4) and GST control (only R4). Only the top 20 and the bottom 10 tetramers/
hexamers are represented as colour-coded heat map, showing z-scores of the motif frequencies for each round. 
Motifs are ordered according to their cumulative (R1–R4) z-score. The top 10 tetramer motifs (highlighted in 
yellow) were used for motif enrichment analysis of specific circRNAs (see panel C). (C) IMP3-binding motif 
enrichment in IMP3-associated circRNAs. The sum of the top ten tetramer motif counts in each of the IMP3 
target circRNAs was determined (left part) and compared with a non-target group of circRNAs (n = 117). This 
is represented by a kernel density estimation plot with group median values shown by vertical lines (p-value 
1.077e-07; Welch two sample t-test; right part).
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Sequencing was performed on an Illumina MiSeq instrument (75 bp single-end reads). For details on iCLIP 
experimental procedures and data analysis, see Rossbach et al.27 and references therein.
Identification of IMP3-associated circRNPs. RNA co-immunoprecipitation. Cell lysates were prepared 
in RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 5 mM EDTA, 1% NP-40, 0.1% SDS) and subsequently 
cleared by centrifugation as well as by pre-incubation with protein-G dynabeads (Life technologies) without anti-
bodies. Antibody binding was performed o/n at 4 °C, using a polyclonal IMP3 antibody (Millipore) and as mock 
control, FLAG-antibody (Sigma-Aldrich). Bead capturing was carried out for one hour at room temperature with 
protein-G dynabeads, and protein-RNA complexes were washed five times with 500 μ l washing buffer (50 mM 
Tris-HCl pH 7.4, 150/300/600 mM NaCl, 0.05% Tween-20), increasing the stringency during the washing steps. 
RNA from the input (5%) and from the immunoprecipitated (IP) fractions was extracted by TRIzol (Ambion), 
followed by RQ1 DNase (Promega) digestion and ethanol precipitation. cDNA synthesis and RT-PCR assays are 
described below. RNA from co-IP experiments (mock-IP and IMP3-IP) was used for cDNA library preparation, 
using the TruSeq stranded total RNA sample preparation kit (Illumina) according to the manufacturer’s proto-
col starting with RNA fragmentation. Libraries were sequenced on a HiSeq instrument (paired-end, 2 × 100 bp, 
Illumina). Immunoprecipitation from gradient fractions was done as described above, starting with 100 μ l of 
glycerol gradient fractions. The IP was carried out with a monoclonal IMP3 antibody and a monoclonal eIF4E 
antibody as mock control (Santa Cruz Biotechnology).
RNA-seq data analysis. Sequence reads were aligned to the human genome sequence (hg19) using STAR, an 
ultrafast universal RNA-seq aligner with chimeric alignment options28. Chimeric mapped reads were selected as 
circRNA-specific junction reads by applying four additional criteria:
(1) Sequence read map to the same chromosome and the same strand, with the two sequence segments mapping 
to the genomic region in reverse order.
(2) The overhang spanning the “back-spliced” junction is ≥ 12 nts.
(3) The alignment score of the chimeric mapped reads (using column 14:aS of Standard SAM attributes) must be 
greater (> 2) than the linear alignment with genomic sequences and annotated transcripts (Comprehensive 
Gene Annotation Set from GENCODE Version 19).
(4) Both 5′ and 3′ splice sites are either annotated or conform to canonical splice sites. The circRNA abundance 
was predicted on the basis of circRNA specific junction read counts.
Validation of IMP3-associated circRNAs. RNase R treatment. HepG2 total RNA (2 μ g) was treated 
with or without RNase R (2.5 U/μ g, Epicentre) for 20 min at 37 °C. RNA was phenolized, ethanol-precipitated, 
and 20% were used for RT-PCR as described below.
RT-PCR. RNA from gradient fractions or immunoprecipitated RNA was extracted by TRIzol (Ambion). cDNA 
was prepared by reverse transcription of 1 μ g total RNA (RNase R assay), 10% of RNA from gradient fractions, 
or 10% of the coimmunoprecipitated RNAs (input/IP), using the qScript flex cDNA synthesis kit (Quanta) and 
random hexamer primers. Circular isoforms were PCR-amplified with divergent primers detecting the circRNA 
junction and linear isoforms with primers detecting the canonical splice junction downstream of the circRNA 
producing exons (for primer design, see ref. 29). PCR products were analyzed on 2% agarose gels (for primer 
sequences, see Supplementary Table S2).
Real-time PCR was carried out, using PerfeCTa SYBR Green Fast-Mix (Quanta) and an Eppendorf realplex2 
thermocycler. Primer efficiencies were determined by four serial dilutions of cDNA derived from total RNA 
(R2 = 0,99, slope = − 3.46 to − 4.15). The fraction of bound target RNAs in co-IP assays was calculated from tech-
nical triplicates by the Δ Δ Ct-method, with each target normalized to the corresponding input fraction (results 
represented as percent of the input). Biological replicates were used to calculate standard deviations.
Western Blotting. Western blotting was performed with 1% of glycerol gradient fractions and a polyclonal IMP3 
antibody (Millipore), which was secondarily detected with an anti-rabbit antibody.
SELEX-seq and motif analysis of IMP3-RNA binding. Protein expression and purification. The IMP3 
(IGF2BP3) open reading frame was PCR-amplified with IMP3_fwd/IMP3_TEV_His_rev primers, including 
His-tag and TEV-cleavage site, and cloned (EcoRI, XhoI) into the pGEX-6P2 expression vector (GE Healthcare). 
The expression of the GST-IMP3-TEV-His fusion protein was induced by IPTG (1 mM) in E. coli BL21, fol-
lowed by a two-step purification. Cells were lysed in His lysis and washing buffer (50 mM NaH2PO4 pH 8.0, 
2 M NaCl, 50 mM imidazole, 10 mM 2-mercaptoethanol, 10% glycerol, 2% Triton X-100) by sonication (three 
times 20 sec). The fusion protein was purified from cell lysate by incubation with Ni-NTA agarose (Qiagen) and 
subsequent elution (50 mM NaH2PO4 pH 8.0, 300 mM NaCl, 250 mM imidazole). The His tag was cleaved off 
(AcTEV-protease, 4 °C o/n, Life Technologies), and the remaining protein was purified in a second step via the 
GST tag (glutathione-Sepharose beads, GE Healthcare). SELEX selections were carried out with the fusion pro-
tein bound to glutathione-Sepharose.
SELEX (systematic evolution of ligands by exponential enrichment). An RNA pool with a degenerated sequence 
of 20 nucleotides was prepared by T7 transcription, using as a template annealed SLX-N20 and T7-fw oligonu-
cleotides (T7 High-Yield Kit, NEB). The selection was performed in a total volume of 200 μ l (10 mM Tris-HCl pH 
7.5, 100 mM KCl, 2.5 mM MgCl2, 0.1% Triton X-100, Roche protease inhibitor) with 40 pmol GST-IMP3 or GST 
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(as negative control) bound to pre-blocked glutathione-Sepharose beads (GE Healthcare) and 4 nmol SLX-N20 
transcript. After a 20 min incubation at room temperature, the samples were washed three times with 1 ml of 
washing buffer (10 mM Tris-HCl pH 7.5, 100/300/600 mM KCl, 2.5 mM MgCl2, 0.1% Triton X-100), treated with 
proteinase K (Roth), phenol/chloroform extracted, and ethanol precipitated. The stringency of washing steps 
was increased during the rounds of selection (R1: 3 × 100 mM ; R2: 2 × 100 mM, 1 × 300 mM ; R3: 1 × 100 mM, 
2 × 300 mM ; R4: 1 × 300 mM and 2 × 600 mM KCl washing buffer).
Selected RNAs were reverse-transcribed (qScript Flex cDNA Synthesis Kit, Quanta), using the SLX_RT 
reverse primer, followed by PCR amplification with SLX_RT and SLX_T7-fw primers (16 cycles). Transcripts for 
the next round of selection were produced by in vitro transcription. After four rounds of selection, RNA aliquots 
from each round and from the fourth round of GST selection were used for barcoding by reverse transcription 
with the SLX_R13-16 (GST-IMP3) and SLX_R18 (GST) reverse primers. cDNA libraries were amplified by PCR 
(17 cycles; SLX_Sol-5xN_fwd and SLX_Sol_rev). All libraries were pooled in equal amounts and purified by 
Caliper (XT DNA 750 assay kit, Perkin-Elmer). The final library pool was subjected to high-throughput sequenc-
ing on a MiSeq instrument (single-read 100 bp, Illumina). For primer sequences, see Supplementary Table S2.
SELEX-seq data analysis of RNA binding of IMP3 protein. Sequence reads were first sample-barcode sorted, 
trimmed by PCR primer sequences on both ends, and further random-barcode filtered to obtain 18- to 20-nt 
sequence tags of the enriched RNA pools (numbers of filtered sequence tags given in Fig. 5A). The numbers 
of filtered sequence tags (from each SELEX round) containing either of the 256 or 4096 possible tetramer or 
hexamer motifs, respectively, was summarized, and the z-score values were calculated for enrichment of each 
motif.
IMP3 non-target circRNA group. To derive a group of circRNAs well-expressed in HepG2 cells, RNA-seq data 
from HepG2 whole cells [poly(A)minus selection; generated by ENCODE Consortium Long RNA-seq] were 
analyzed. The expression of circRNAs was determined by circRNA-specific junction counts. Based on three cri-
teria (circular-junction counts ≥ 10; derived from exons of protein-coding genes; not detected in our IMP3 IP 
experiment), 117 circRNAs were selected as “IMP3 non-target group”.
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Supplementary Figure S1.  
CircRNA-protein complexes in mammalian cells:  
comparing S100, cytoplasmic, and nuclear extracts 
(A/B) Sedimentation profiles of circRNPs from HeLa cells. Cytoplasmic S100 extract 
(S100), cytoplasmic extract (CE), nuclear extract (NE), as well as free RNA (RNA; 
prepared from S100 extract), and S100 and CE extracts after proteinase K treatment 
(S100 extract+PK; CE+PK) were fractionated by glycerol gradient centrifugation (#1-
22 from top to bottom; the last fraction containing the resuspended pellet). The circRNA 
distributions across the gradients were determined by RT-PCR: (A) for three abundant 
circRNAs (CAMSAP1, GLIS3, and HIPK3; related to Fig. 1A), and (B) for two IMP3-
associated circRNAs (CDYL and NFATC3; related to Fig. 3C). The positions of 
ribosomal RNA size markers are indicated (5S, 18S, and 28S), and the brackets mark 
the circRNA vs. circRNP peak fractions from cytoplasmic S100 and cytoplasmic extract 
(CE). The circRNP distribution in nuclear extract (NE) was detectable only for 
CAMSAP1, GLIS3, and HIPK3 circRNAs. The sedimentation of IMP3 protein in 
cytoplasmic S100 extract (S100 extract) and cytoplasmic extract (CE) was visualized 
by Western Blot. 
 
 
Supplementary Figure S2. 
iCLIP analysis of IMP3-RNA interactions in HepG2 cells 
A. Summary of iCLIP sequence reads (left part) and distribution of barcode-filtered 
crosslink tag counts in genome (right part). 
B. Barcode-filtered crosslink tag counts, based on our IMP3 iCLIP-Seq data, are 
represented for these genes: FTL (positive linear mRNA control); CAMSAP1 (negative 
circRNA control); CDYL, NFATC3, and ANKRD17 (IMP3 circRNA targets; with the 
circularizing exons highlighted).  
 
 
 


genomic circRNA motif
gene_symbol start end length(nts) length(nts) HepG2 PANC1 PATU transcript_id circular exons counts*
ARID1A + chr1 27056142 27059283 3142 783 21 61 54 ENST00000457599.2 e2-e4 34
ANKRD17(2) - chr4 73956384 73958017 1634 1634 81 16 251 ENST00000358602.4 e29 119
ANKRD17(1) - chr4 73950966 73958017 7052 1832 43 6 63 ENST00000358602.4 e29,e30 134
ATXN1 - chr6 16326625 16328701 2077 2077 35 17 7 ENST00000436367.1 e7 81
C11orf30 + chr11 76174865 76183884 9020 537 5 7 49 ENST00000533248.1 e7,e8 55
CCAR1 + chr10 70497602 70502326 4725 272 1 2 33 ENST00000541012.1 e4-e6 26
CDC73 + chr1 193172925 193181607 8683 182 1 4 32 ENST00000367435.3 e11-e13 10
CDYL + chr6 4891947 4892613 667 667 53 33 72 ENST00000449732.2 e2 33
CYP24A1 - chr20 52773708 52788209 14502 1106 35 2 85 ENST00000216862.3 e3-e11 48
DROSHA - chr5 31421379 31424578 3200 309 1 9 40 ENST00000513349.1 e27-e29 16
ELK4 - chr1 205585606 205593019 7414 1373 11 24 50 ENST00000357992.4 e2-e5 71
FAT1 - chr4 187627717 187630999 3283 3283 61 11 30 ENST00000441802.2 e2 165
FIP1L1(1) + chr4 54280782 54294350 13569 359 3 0 45 ENST00000358575.5 e10-e12 15
FIP1L1(2) + chr4 54292039 54310270 18232 389 5 8 57 ENST00000358575.5 e11-e15 18
FNDC3B + chr3 171965323 171969331 4009 526 75 139 114 ENST00000416957.1 e5,e6 35
FOXP1 - chr3 71090479 71102924 12446 587 32 1 5 ENST00000468577.1 e3-e6 37
NEIL3(2) + chr4 178274462 178274882 421 421 2 0 70 ENST00000264596.3 e8 29
NEIL3(1) + chr4 178274462 178281831 7370 596 0 6 53 ENST00000264596.3 e8,e9 37
NFATC3(2) + chr16 68155890 68157024 1135 1135 109 31 298 ENST00000575270.1 e2 57
NFATC3(1) + chr16 68155890 68160513 4624 1298 39 9 62 ENST00000575270.1 e2,e3 63
PHC3(1) - chr3 169840379 169847340 6962 1023 8 18 168 ENST00000494943.1 e8,e9 60
PHC3(2) - chr3 169863211 169867032 3822 258 19 21 286 ENST00000494943.1 e5,e6 12
PHC3(3) - chr3 169854207 169867032 12826 505 17 29 398 ENST00000494943.1 e5-e7 34
PTPRA + chr20 2944918 2945848 931 421 6 10 67 ENST00000425918.2 e3,e4 27
R3HDM1 + chr2 136432902 136437894 4993 307 3 13 50 ENST00000409606.1 e19,e20 22
SAMD4A + chr14 55168780 55169298 519 519 5 1 31 ENST00000554335.1 e3 33
SPECC1 + chr17 20107646 20109225 1580 1580 15 4 63 ENST00000395527.4 e4 72
TAB2(1) + chr6 149699154 149700654 1501 1501 6 3 37 ENST00000392282.1 e3 111
TAB2(2) + chr6 149691045 149700654 9610 1692 10 8 62 ENST00000392282.1 e2,e3 119
TEX10 - chr9 103082547 103111654 29108 2211 10 1 37 ENST00000374902.4 e2-11 112
UBAP2(1) - chr9 33948372 33953472 5101 404 3 25 84 ENST00000418786.2 e10,e11 31
UBAP2(2) - chr9 33948372 33956144 7773 472 6 29 64 ENST00000418786.2 e9-e11 38
UBAP2(3) - chr9 33941647 33948585 6939 873 6 17 42 ENST00000418786.2 e11-e14 61
VWA8 - chr13 42385361 42393522 8162 363 3 3 38 ENST00000281496.6 e15-e17 29
chromosome_position           
strand
circRNA-specific junction counts 
* total number of top 10 enriched tetramers (SELEX-based)
Supplementary Table S1. IMP3-associated circRNAs (≥ 30 circRNA-specific junction read counts in at least one cell line) 
Supplementary Table S2. List of oligonucleotides.
Gene Primer name Sequence Method
AFAP1_circ_fwd GAAGGACCATGCTCAGAAGC
AFAP1_circ_rev CACTGCCTTTTTCTCCCTGA
ASAP1_circ_fwd GACTACAACTCGCCCACCAC
ASAP1_circ_rev TGAAACCATGCCTCAGTGAA
ASPH_circ_fwd TCAGAGGTGCTTCAAGGAAAA
ASPH_circ_rev CCAGCAATGCAATCACCATA
ASXL1_circ_fwd GCATGCCTCAATGCTATGCT
ASXL1_circ_rev GGGGAAGTCCCACTTCTCAT
CAMSAP1_circ_fwd CCCTGATGATGGCCTACACT
CAMSAP1_circ_rev TGTGCTCCTGCTCATACTGG
CDYL2_circ_fwd ATGGGTGAATGTGACGTGAA
CDYL2_circ_rev TCCTCACAGTGCAAGAGGTG
CORO1C_circ_fwd ATGGGTTACATGCCCAAGAG
CORO1C_circ_rev ACTGCTGTCACCCTTTCCAC
CRKL_circ_fwd TCATGCATACGCTCAACCTC
CRKL_circ_rev GGTTGGGTGCTGAGACAGAT
EPHB4_circ_fwd CCCGTCATGATTCTCACAGA
EPHB4_circ_rev TTGATTGCCACACAGCTCTC
FARSA_circ_fwd TCCGACAGATCTTCCTGGAG
FARSA_circ_rev CTGGGCTCAGCTCTGTCTCT
GLIS3_circ_fwd GTTTGGAAGCCCTTTTCCTC
GLIS3_circ_rev GATGTCCGGTGGAGACTCAT
GSE1_circ_fwd CCAGCTTTGCCGCCGCGCTG
GSE1_circ_rev GTGGAAAGCATCCCTAGCG
HIPK3_circ_fwd TCGGCCAGTCATGTATCAAA
HIPK3_circ_rev CCCTTAGTGGGAGGATGAGA
LPAR1_circ_fwd TGGCTGCCATCTCTACTTCC
LPAR1_circ_rev CGAAGTCATGCTAGGAGAAGC
SH3PXD2A_circ_fwd GGGATGACTCCGACATCAAC
SH3PXD2A_circ_rev CTCAGCTCCGAGTTCTCCTG
FTL_linE3-4_fwd ATCTTCATGCCCTGGGTTCT
FTL_linE3-4_rev GAGGTTGGTCAGGTGGTCA
ANKRD17_linE31-32_fwd TCTGCACGTATCAGGCAAAC
ANKRD17_linE31-32_rev ATTTCCCATCCCAGGGTTAC
ANKRD17_circE29-30_fwd (1) CAGGAGGTCAGATGTACGGA
ANKRD17_circE29-30_rev (1) TCTTGTTGATTCAGTGCCACC
ARID1A_linE5-6_fwd AGTGTTGCTCAGTCTCGCTC
ARID1A_linE5-6_rev CGATCTTGGGCAATGCTTGA
ARID1A_circE2-4_fwd CCAGTAAGGGAGGGCAAGAA
ARID1A_circE2-4_rev TGCTGCGAGTATGGGTTAGT
GSE1
AFAP1
ASAP1
ASPH
ASXL1
CAMSAP1
CDYL2
CORO1C
CRKL
EPHB4
FARSA
GLIS3
HIPK3
LPAR1
SH3PXD2A
FTL
ANKRD17
ARID1A
RT-PCR
RT-PCR
RT-PCR
RT-PCR
RT-PCR
RT-PCR/RT-qPCR
RT-PCR
RT-PCR
RT-PCR
RT-PCR
RT-PCR
RT-PCR
RT-PCR
RT-PCR
Identification of IMP3-associated circRNAs
Gradient sedimentation analysis
RT-PCR
RT-PCR/RT-qPCR
RT-PCR/RT-qPCR
RT-PCR
Supplementary Table S2. List of oligonucleotides.
Gene Primer name Sequence Method
PHC3_linE10-11_fwd TCAGTGTGTGTTCAGCCAGA
PHC3_linE10-11_rev CTGAAGCACTGACTGATGCC
PHC3_circE8-9_fwd (1) ACAGTGGGGAGAGGAGAAGA
PHC3_circE8-9_rev (1) TGGGAAACTTTGGAAGGTGG
CDYL_linE5-6_fwd GGCTTCACCCACATCTTGTT
CDYL_linE5-6 _rev GTACCAGCTTGCTGTCATCG
CDYL_circE4_fwd CAGGCTTAGCTGTTAACGGG
CDYL_circE4_rev TGTCATAGCCTTTCCACCGA
ELK4_linE4-5_fwd ACTCTCAGTCCTGTTGCTCC
ELK4_linE4-5_rev ACAGAGTGAATGGCCCATGA
ELK4_circE2-5_fwd GTGGAATGAGAGAACCGAGGA
ELK4_circE2-5_rev GTGGAATGAGAGAACCGAGGA
FNDC3B_linE7-8_fwd GTTGGAAGTAAAGAGGGTGCA
FNDC3B_linE7-8_rev CCACCTCGTAACTGTAGGGG
FNDC3B_circE5-6_fwd CGGTAGTGGTCCCGGAATTA
FNDC3B_circE5-6_rev TGGGTGACATCATGGGAACT
NEIL3_lin6-7_fwd GTCCTAATTGTGGTCAGTGCC
NEIL3_lin6-7_rev CCACCCTGCTAGATGTCCAA
NEIL3_circE8_fwd (2) AGCTGCAACCCTGGATATTCT
NEIL3_circE8_rev (2) AGAGTTGTAGTTCCAAATGCAGT
NFATC3_linE4-5_fwd CGACCTCATGCATTTTACCA
NFATC3_linE4-5_rev TCTGAATTGCGGAGTTTCAA
NFATC3_circE2_fwd (1+2) ACCTGGAGCAAACCAAAGCC
NFATC3_circE2_rev (2) TGTGGTAAGCAAAGTGGTGTG
NFATC3_circE3_fwd (1) TGAAACTGAAGGTAGCCGAGG
IMP3_fwd TGATGAACAAACTGTATATCGGAA
IMP3_TEV_His_rev TGACCTCGAGTTAATGATGATGATGATGATGACCTTGAAAATAAAATTTTCCTTCCGTCTTGACTGAGGTG
SLX_N20 GCGTCTCGAGCGTAGTTANNNNNNNNNNNNNNNNNNNNAGTCGGCATCTTGGTACCTATAGTGAGTCGTATTA
T7_fwd TAATACGACTCACTATAGGG
SLX_RT GCGTCTCGAGCGTAGTTA
SLX_T7_fwd TAATACGACTCACTATAGGGTACCAAGATGCCGACT
Selection round 1 SLX_R13 CAAGCAGAAGACGGCATACGAGATCGGTCTCGGCATTCCTGNNATATNNNGCGTCTCGAGCGTAGTTA
Selection round 2 SLX_R14 CAAGCAGAAGACGGCATACGAGATCGGTCTCGGCATTCCTGNNGGCANNNGCGTCTCGAGCGTAGTTA
Selection round 3 SLX_R15 CAAGCAGAAGACGGCATACGAGATCGGTCTCGGCATTCCTGNNTGTANNNGCGTCTCGAGCGTAGTTA
Selection round 4 SLX_R16 CAAGCAGAAGACGGCATACGAGATCGGTCTCGGCATTCCTGNNGGACNNNGCGTCTCGAGCGTAGTTA
Selection round 4 (GST) SLX_R18 CAAGCAGAAGACGGCATACGAGATCGGTCTCGGCATTCCTGNNGCGTNNNGCGTCTCGAGCGTAGTTA
SLX_Sol-5xN_fwd AATGATACGGCGACGTCCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNNGGGTACCAAGATGCCGACT
SLX_Sol_rev CAAGCAGAAGACGGCATACG
NFATC3
IMP3
Random RNA pool
PHC3
CDYL
ELK4
FNDC3B
NEIL3
Library 
preparation
SELEX-Seq and motif analysis of IMP3 RNA binding
RT-PCR
RT-PCR
RT-PCR
RT-PCR/RT-qPCR
Cloning
SELEX
RT-PCR
RT-PCR/RT-qPCR
